{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"271.3","value":"5570"},{"groupId":"OG001","spread":"481.1","value":"4690"},{"groupId":"OG002","spread":"67.5","value":"14300"},{"groupId":"OG003","spread":"109.3","value":"6950"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"11"}],"units":"Participants"}],"description":"Cmax is the maximum (peak) observed in peripheral blood or other body fluid drug concentration after single dose administration. Cmax, based on the transgene level data by qPCR, was summarized by Month 3 response, per Independent Review Committee assessment. The reported Cmax is the summary of maximum level observed based on the data from each patient and based on all the data that's been collected for up to 60 months in a patient.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US.","id":"OG000","title":"Tisagenlecleucel - Main Cohort: CR/PR"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US","id":"OG001","title":"Tisagenlecleucel - Main Cohort: SD/PD/UNK"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"OG002","title":"Tisagenlecleucel - Cohort A: CR/PR"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"OG003","title":"Tisagenlecleucel - Cohort A: SD/PD/UNK"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Full Analysis Set (FAS): Comprised all patients who received infusion of tisagenlecleucel with valid PK assessments.","reportingStatus":"POSTED","timeFrame":"60 months","title":"Pharmacokinetics (Pk): Cmax","type":"SECONDARY","unitOfMeasure":"copies/ug"}